To include your compound in the COVID-19 Resource Center, submit it here.
Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury